Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company that describes itself as committed to delivering a new class of differentiated one-time curative genetic therapies using its proprietary Prime Editing platform. The PRME news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how this Prime Editing strategy progresses from research to clinical data and corporate milestones.
According to its public announcements, Prime Medicine is advancing a diversified portfolio of investigational programs focused on liver, lung, and immunology and oncology. News items highlight specific programs such as PM577 for H1069Q-driven Wilson’s Disease, PM647 for Alpha-1 Antitrypsin Deficiency, an in vivo Cystic Fibrosis program supported by the Cystic Fibrosis Foundation, and PM359 for p47phox chronic granulomatous disease. Updates may include preclinical data presentations, first-in-human clinical data, and information about how Prime Editing is being applied across these indications.
Investors and observers can also use the PRME news page to follow corporate developments disclosed by the company, such as participation in healthcare and genetic medicines conferences, leadership appointments, financing transactions, and strategic collaborations, including efforts with Bristol Myers Squibb on Prime Edited CAR-T products. Because Prime Medicine regularly issues press releases in connection with quarterly financial results, pipeline updates, and investor events, the news stream offers a way to track changes in its pipeline priorities, regulatory plans, and capital markets activity over time.
By reviewing the PRME news feed, users can see how Prime Medicine communicates progress on its Prime Editing platform, key disease programs, and business strategy. Bookmarking this page provides a single location to review recent announcements, clinical and preclinical data disclosures, and other material updates that the company has chosen to release publicly.
Prime Medicine (Nasdaq: PRME) will host a virtual KOL event on Nov 12, 2025 at 8:00am ET to present its liver disease franchise and Wilson’s Disease strategy. The company said it remains on track to file an IND/CTA for PM577 in the first half of 2026, with initial clinical data expected in 2027. Presenters include company management and Dr. Michael Schilsky, covering Prime Editing platform modularity, the unmet need in Wilson’s Disease, and development plans. The live webcast and presentation materials will be available on Prime Medicine’s investor relations site, with an archived replay after the event.
Prime Medicine (Nasdaq: PRME) announced management will participate in two investor conferences in October 2025. A fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference will be available on demand beginning October 14, 2025, with virtual 1x1 meetings on October 15, 2025. Allan Reine, M.D., will join a panel, “Genome Editing: Next Wave Technologies,” and host 1x1 meetings at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025 at 8:45 a.m. ET in New York.
Live audio webcasts and replays will be available under Events & Presentations on the company website, with replays accessible for 90 days after each event.
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced its participation in two upcoming investor conferences in September 2025:
The company will present at Citi's 2025 Biopharma Back to School Conference on September 2 at 4:45 p.m. ET in Boston, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 1:05 p.m. ET in New York. Live webcasts will be available on Prime Medicine's website, with replays accessible for 90 days after each event.
Prime Medicine (NASDAQ: PRME) reported Q2 2025 financial results and significant business updates. The company announced positive clinical data from two patients in their Phase 1/2 CGD trial, demonstrating the first clinical proof-of-concept for Prime Editing technology. Prime Medicine completed a follow-on offering raising $144.2 million and secured up to $24 million in additional funding from the Cystic Fibrosis Foundation.
The company reported a Q2 2025 net loss of $52.6 million, with R&D expenses of $41.4 million and G&A expenses of $13.1 million. Under new CEO Allan Reine's leadership, Prime Medicine is focusing on advancing its liver franchise programs (Wilson's Disease and Alpha-1 Antitrypsin Deficiency) and partnership-funded initiatives. The company's pro-forma cash position of $259.6 million is expected to fund operations into 2027.
Prime Medicine (Nasdaq: PRME) has successfully completed its public offering of 43.7 million shares of common stock at $3.30 per share, including the full exercise of the underwriters' option for 5.7 million additional shares. The biotechnology company, focused on developing curative genetic therapies, raised approximately $144.2 million in gross proceeds before deducting expenses.
The offering included a notable sale of 1,818,181 shares to the Cystic Fibrosis Foundation, for which underwriters received no commissions. TD Cowen and BMO Capital Markets served as joint book-running managers for the offering, which was conducted under Prime Medicine's previously filed shelf registration statement.
Prime Medicine (Nasdaq: PRME) has announced the pricing of a public offering of 38,000,000 shares of common stock at $3.30 per share. The biotechnology company expects to raise approximately $125.4 million in gross proceeds before deducting expenses.
The offering includes a notable arrangement with the Cystic Fibrosis Foundation, which will purchase 1,818,181 shares without underwriter commissions. Additionally, underwriters have a 30-day option to purchase up to 5,700,000 additional shares. The offering is expected to close around August 1, 2025, with TD Cowen and BMO Capital Markets serving as joint book-running managers.
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced a proposed public offering of common stock. The company will grant underwriters a 30-day option to purchase an additional 15% of the offered shares.
The offering will be managed by TD Cowen and BMO Capital Markets as joint book-running managers. The shares will be offered through a previously filed shelf registration statement that became effective on November 13, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
Prime Medicine (Nasdaq: PRME) has secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to accelerate the development of Prime Editors for treating cystic fibrosis (CF). The funding includes a $6 million equity investment and will be provided in two tranches, subject to certain conditions and milestones.
The company's Prime Editing technology aims to permanently correct CF-related lung disease through multiple hotspot Prime Editors that could potentially benefit over 93% of CF patients. Initially, Prime Medicine will focus on targeting the G542X mutation, one of the most common CF-causing nonsense mutations currently lacking available therapies.
Prime Medicine (NASDAQ: PRME), a biotechnology company focused on developing one-time curative genetic therapies, has announced its participation in two major upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 10:30 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:40 p.m. ET in Miami Beach. Both presentations will be available via live audio webcasts on the company's website, with replays accessible for 90 days following each event.